Latest Sagent Pharmaceuticals Inc (SGNT) Headlines
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Two Lots of Zoledronic Acid Injection, 5mg/100mL due to Potential Lack of Container Integrity
GlobeNewswire - Tue Mar 04, 11:04AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of two lots of Zoledronic Acid Injection, 5mg/100mL premix bag (NDC number 25021-830-82) distributed by Sagent. Sagent has initiated this voluntary recall of Zoledronic Acid Injection, 5mg/100mL to the user level due to the discovery of four (4) leaking premix bags detected during an investigation conducted in response to a product complaint. The subject bags were not administered to patients as the leakage was readily apparent.
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Tue Feb 11, 6:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the fourth quarter and fiscal year ended December 31, 2013.
Pentagon Awards $1.23 Billion in Defense Contracts Tuesday
Rich Smith, The Motley Fool - Motley Fool - Tue Feb 04, 5:30PM CST
The Department of Defense awarded only seven defense contracts Tuesday, yet still managed to hand out $1.23 billion worth of work. More than half the funds awarded went to a single recipient, privately held government contractor KS International...
Sagent Pharmaceuticals opens National Research Centre in Chengdu, China
M2 - Tue Feb 04, 6:10AM CST
US-based specialist pharmaceutical company Sagent Pharmaceuticals Inc (NasdaqGS:SGNT) reported on Monday the opening of its National Research Centre (NRC) in China.
Sagent Pharmaceuticals Launches National Research Center in Chengdu, China
GlobeNewswire - Mon Feb 03, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced the launch of its National Research Center ("NRC") in Chengdu, China. Based in Chengdu's Bio-Technology Park, the NRC will focus on process and method development of technically challenging specialty injectable pharmaceuticals.
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Jan 30, 3:30PM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2013 fourth quarter and fiscal year end pre-market on Tuesday, February 11, 2014 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Regulus (RGLS) Jumps: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 8:46AM CST
Regulus was a big mover last session, with shares rising nearly 6%.
Sucampo (SCMP) Worth Watching: Stock Rises 11.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 8:25AM CST
Sucampo Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
IGI, Laboratories (IG) Soars: Stock Adds 10.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 7:57AM CST
IGI, Laboratories, Inc. (IG) was a big mover last session, as the company saw its shares rise over 10% on the day.
Tesaro (TSRO) Jumps: Stock Moves 8.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 8:46AM CST
Tesaro was a big mover last session, with shares rising above 8%.
Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 7:37AM CST
Flamel Technologies SA was a big mover last session, as the company saw its shares rise almost 9% on the day.
Receptos (RCPT) in Focus: Stock Moves 12.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 10, 8:46AM CST
Receptos was a big mover last session, with shares rising nearly 13%.
Sagent Pharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 08, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 32 Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2014 at 8:30 a.m. PT (10:30 a.m. CT/11:30 a.m. ET). A live webcast of the conference will be available on the Company's website at: http://investor.sagentpharma.com/events.cfm. In order to register and download any necessary software, please log on 10 minutes prior to the start of the webcast.
Why You Need To Watch Johnson & Johnson, Synergy, Sagent, and Supernus This Morning
Leo Sun, The Motley Fool - Motley Fool - Tue Dec 24, 8:04AM CST
Follow @leokornsun // full story)
Sagent Pharmaceuticals Announces the Launch of Octreotide Acetate Injection
GlobeNewswire - Mon Dec 23, 1:30PM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Octreotide Acetate Injection, a Somatostatin Analog, in five vial presentations. According to IMS, for the 12 months ending October 2013, the US market for Octreotide Acetate Injection approximated $45 million. As with all products in Sagent's portfolio, Octreotide features the company's PreventIV Measures packaging and labeling, designed to help reduce medication errors.
Improved Stock Price Performance of HealthCare Related Companies - Research Report on Omega, BioScrip, Accuray, Stereotaxis and Sagent Pharmaceuticals
PR Newswire - Fri Dec 20, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Omega Healthcare Investors Inc. (NYSE: OHI), BioScrip Inc. (NASDAQ: BIOS), Accuray Incorporated (NASDAQ: ARAY), Stereotaxis Inc. (NASDAQ: STXS), and Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 16, 7:05AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.
Study Results, Private Placements, Collaborations, Product Launches, and Public Offerings - Research Report on ViroPharma, Incyte, Tenet Healthcare, Sagent Pharmaceuticals and Chelsea Therapeutics
PR Newswire - Fri Nov 22, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ViroPharma Inc. (NASDAQ: VPHM), Incyte Corporation (NASDAQ: INCY), Tenet Healthcare Corp. (NYSE: THC), Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Sagent Pharmaceuticals Announces the Launch of Propofol Injectable Emulsion USP 1%
GlobeNewswire - Mon Nov 18, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Propofol Injectable Emulsion USP 1%, in two Single-Dose, Single-Patient vial presentations of 20 mL and 100 mL. A 50 mL Single-Dose, Single-Patient vial presentation will be released shortly. According to IMS, for the 12 months ending September 2013, the US market for Propofol approximated $230 million.
Presentations and Quarterly Reports - Research Report on NPS, Zalicus, Charles River, Insulet, and Sagent
PR Newswire - Thu Nov 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Zalicus Inc. (NASDAQ: ZLCS), Charles River Laboratories International, Inc. (NYSE: CRL), Insulet Corporation (NASDAQ: PODD), and Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Two Lots of Zoledronic Acid Injection, 5mg/100mL due to Potential Lack of Container Integrity
GlobeNewswire - Tue Mar 04, 11:04AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of two lots of Zoledronic Acid Injection, 5mg/100mL premix bag (NDC number 25021-830-82) distributed by Sagent. Sagent has initiated this voluntary recall of Zoledronic Acid Injection, 5mg/100mL to the user level due to the discovery of four (4) leaking premix bags detected during an investigation conducted in response to a product complaint. The subject bags were not administered to patients as the leakage was readily apparent.
Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Results
GlobeNewswire - Tue Feb 11, 6:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the fourth quarter and fiscal year ended December 31, 2013.
Pentagon Awards $1.23 Billion in Defense Contracts Tuesday
Rich Smith, The Motley Fool - Motley Fool - Tue Feb 04, 5:30PM CST
The Department of Defense awarded only seven defense contracts Tuesday, yet still managed to hand out $1.23 billion worth of work. More than half the funds awarded went to a single recipient, privately held government contractor KS International...
Sagent Pharmaceuticals opens National Research Centre in Chengdu, China
M2 - Tue Feb 04, 6:10AM CST
US-based specialist pharmaceutical company Sagent Pharmaceuticals Inc (NasdaqGS:SGNT) reported on Monday the opening of its National Research Centre (NRC) in China.
Sagent Pharmaceuticals Launches National Research Center in Chengdu, China
GlobeNewswire - Mon Feb 03, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced the launch of its National Research Center ("NRC") in Chengdu, China. Based in Chengdu's Bio-Technology Park, the NRC will focus on process and method development of technically challenging specialty injectable pharmaceuticals.
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Jan 30, 3:30PM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will release financial results for the 2013 fourth quarter and fiscal year end pre-market on Tuesday, February 11, 2014 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Regulus (RGLS) Jumps: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 17, 8:46AM CST
Regulus was a big mover last session, with shares rising nearly 6%.
Sucampo (SCMP) Worth Watching: Stock Rises 11.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 8:25AM CST
Sucampo Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
IGI, Laboratories (IG) Soars: Stock Adds 10.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 7:57AM CST
IGI, Laboratories, Inc. (IG) was a big mover last session, as the company saw its shares rise over 10% on the day.
Tesaro (TSRO) Jumps: Stock Moves 8.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 8:46AM CST
Tesaro was a big mover last session, with shares rising above 8%.
Flamel Technologies (FLML) in Focus: Stock Jumps 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 7:37AM CST
Flamel Technologies SA was a big mover last session, as the company saw its shares rise almost 9% on the day.
Receptos (RCPT) in Focus: Stock Moves 12.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 10, 8:46AM CST
Receptos was a big mover last session, with shares rising nearly 13%.
Sagent Pharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 08, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 32 Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2014 at 8:30 a.m. PT (10:30 a.m. CT/11:30 a.m. ET). A live webcast of the conference will be available on the Company's website at: http://investor.sagentpharma.com/events.cfm. In order to register and download any necessary software, please log on 10 minutes prior to the start of the webcast.
Why You Need To Watch Johnson & Johnson, Synergy, Sagent, and Supernus This Morning
Leo Sun, The Motley Fool - Motley Fool - Tue Dec 24, 8:04AM CST
Follow @leokornsun // full story)
Sagent Pharmaceuticals Announces the Launch of Octreotide Acetate Injection
GlobeNewswire - Mon Dec 23, 1:30PM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Octreotide Acetate Injection, a Somatostatin Analog, in five vial presentations. According to IMS, for the 12 months ending October 2013, the US market for Octreotide Acetate Injection approximated $45 million. As with all products in Sagent's portfolio, Octreotide features the company's PreventIV Measures packaging and labeling, designed to help reduce medication errors.
Improved Stock Price Performance of HealthCare Related Companies - Research Report on Omega, BioScrip, Accuray, Stereotaxis and Sagent Pharmaceuticals
PR Newswire - Fri Dec 20, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Omega Healthcare Investors Inc. (NYSE: OHI), BioScrip Inc. (NASDAQ: BIOS), Accuray Incorporated (NASDAQ: ARAY), Stereotaxis Inc. (NASDAQ: STXS), and Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 16, 7:05AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.
Study Results, Private Placements, Collaborations, Product Launches, and Public Offerings - Research Report on ViroPharma, Incyte, Tenet Healthcare, Sagent Pharmaceuticals and Chelsea Therapeutics
PR Newswire - Fri Nov 22, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting ViroPharma Inc. (NASDAQ: VPHM), Incyte Corporation (NASDAQ: INCY), Tenet Healthcare Corp. (NYSE: THC), Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Sagent Pharmaceuticals Announces the Launch of Propofol Injectable Emulsion USP 1%
GlobeNewswire - Mon Nov 18, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Propofol Injectable Emulsion USP 1%, in two Single-Dose, Single-Patient vial presentations of 20 mL and 100 mL. A 50 mL Single-Dose, Single-Patient vial presentation will be released shortly. According to IMS, for the 12 months ending September 2013, the US market for Propofol approximated $230 million.
Presentations and Quarterly Reports - Research Report on NPS, Zalicus, Charles River, Insulet, and Sagent
PR Newswire - Thu Nov 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Zalicus Inc. (NASDAQ: ZLCS), Charles River Laboratories International, Inc. (NYSE: CRL), Insulet Corporation (NASDAQ: PODD), and Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
